Unlocking the Power of Precision Medicine with Advanced Genetic Testing
As a pioneer of precision medicine for over 45 years, Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, including Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), now with RNAseq, and focused panels. Through a joint venture of H.U. Group Holdings, Inc. and Baylor College of Medicine, Baylor Genetics combines rapid and comprehensive precision diagnostics options with the support of genetic counselors to help clinicians avoid a lengthy diagnostic odyssey for their patients, guide medical management, and ensure no patient with a genetic disorder gets left behind.
For patients and families facing neurodevelopmental disorders (NDD), genetic testing is a critical step in the diagnostic journey. Most NDD indicators lead families and providers to WES and WGS because of the comprehensiveness of these tests. Indications for WES testing includes autism spectrum disorders (ASD), developmental delay (DD), intellectual disability (ID), and other NDDs.
In addition to WES and WGS, Baylor Genetics’ Neurodevelopmental Disorders Panel is designed for patients affected by a suspected or clinically diagnosed NDD, ASD, ID, and/or DD. This panel analyzes 236 genes associated with these conditions enabling robust detection of SNVs, INDELs, and CNVs at exceptional read depths.